ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
January 27, 2026 | HEOR, Market Access, RWE, Top Trends, ispor, organization
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on our ability to influence decisions under constraint.
Read ISPOR’s Top 10 HEOR Trends for 2026-2027 in isolation, and nothing seems radical. But as a system, the message is unmistakable. We have hit a structural inflection point in this industry.
For years, the mandate for HEOR organizations was simple: generate evidence.
Today, that mandate has shifted. We are no longer being evaluated on our ability to produce data; we are being judged on our ability to influence decisions under constraint. That requires adaptable teams, cross-functional perspectives, and the ability to evolve strategy in real-time.
The central question for leadership is no longer, “Can we generate the data?” That problem is largely solved. The question now is, “What evidence will have the most impact on decision-making?”
The selection problem
We are drowning in the data lakes. The explosion of AI and Real-World Evidence (RWE) means we can run almost any analysis we can dream up. But just because we can analyze everything doesn’t mean we should.
Abundance is becoming our biggest liability. Organizations that analyze everything will lose to those that curate. The advantage lies in distinguishing what is technically interesting from what is defensible under scrutiny. Many strategies quietly fail right here, mistaking volume for insight…
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group’s recent expansion of its real-world data…
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural…
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to…
Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
We are pleased to share that The Evidence Base have carried out a ‘deep dive’ into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights…
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group’s poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey’ was recently named as…
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition…
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities…
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life…
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme ‘Advancing Healthcare’ featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one…